Use of aldosterone antagonists to inhibit myocardial fibrosis

Details Use of aldosterone antagonists to inhibit myocardial fibrosis Use of aldosterone antagonists to inhibit myocardial fibrosis

1996-03-28

1997-09-16

Cook, Rebecca

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514173, A61K 3171

Patent

active

056681240

ABSTRACT:
This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).

REFERENCES:
patent: 4003996 (1977-01-01), Pappo et al.
American Journal of Cardiology, Klug et al, "Role of Mechanical and Hormonal Factors in Cardiac Remodeling and the Biologic Limits of Myocardial Adaptation," Jan. 21, 1993, vol. 71, No. 3, pp. 46A-54A.
Journal of Molecular and Cellular Cardiology, Brilla et al, "Anti-Aldosterone Treatment and the Prevention of Myocardial Fibrosis in Primary and Secondary Hyperaldosteronism," May 1993, vol. 25, No. 5, pp. 563-575.
American Journal of Cardiology, Brilla et al., "Antifibrotic Effects of Spironolactone in Preventing Myocardial Fibrosis in Systemic Arterial Hypertension," Jan. 21, 1993, vol. 71, No. 3 pp. 12A-16A.
Journal of Pharmacology and Experimental Therapeutics, "Three New Epoxy-Spirolactone Derivatives; Characterization in vivo and in vitro," Feb. 1987, vol. 240, No. 2, pp. 650-656.
Budesverbrand D. Pharm. Ind. E.V., "Rote Liste, " 1987 Editio Cantor, Aulendorft/Wortt.
Remington Pharmaceutical Sciences, 1975, pp. 867-868.
Doering, C.W., et al, "Collagen Network Remodeling and Diastolic Stiffness of the Rat Left Ventricle With Pressure Overload Hypertrophy," Cardiovasc. Res. 22: 686-695 (1988).
Brilla, C.G., et al., "Remodeling of the Rat Right and Left Ventricle in Experimental Hypertension, " Circ. Res. 67: 1355-1364 (1990).
Weber, K.T., et al., "Structual Remodeling of Myocardial Collagen in Systemic Hypertension: Functional Consequences and Potential Therapy," Heart Failure 6: 129-137 (1990).
Weber, K.T., et al., "Myocardial Remodeling and Pathologic Hypertrophy," Hospital Practice 26(4): 73-80 (1991).
Andreoli, T.E., Introduction: Modern Aspects of Congestive Heart Failure, "Hospital Practice" 26(4): 7-8 (1991).
Brilla, C.G., et al., abstract, "Myocardial Fibrosis in Experimental Hypertension: Potential Role of Fibroblast Corticoid Receptors," J. Hypertension 8: S8 (1990).
Weber, K. T., and Brilla, C.G., "Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin-Angiotension-Aldosterone System," Circulation 83: 1849-1865 (Jun. 1991).
Weber,K.T., and Brilla, C.G., "Myocardial Fibrosis and Elevations in Plasma Aldosterone in Arterial Hypertension," Aldosterone: Fundamental Aspects 215: 117-120 (1991).
Brilla, C.G. and Weber, K.T., "Prevention of Myocardial Fibrosis in Hypertension: Role of Fibroblast Corticoid Receptors and Spironolactone," Proceedings of the 75th Annual Meeting of the Fed. of Amer. Societies for Exper. Biology, 1991, abstract no. A1256, published Apr. 21, 1991.
Remingtons Pharmaceutical Sciences, 15 edition, 1975 pp. 867-868.
C. Brilla et al, Myocardial Fibrosis in Experimental Hypertension., J. Hypest. 813:58 supplement, abstract 1990.

Affiliated with

Also associated with

Rating

Use of aldosterone antagonists to inhibit myocardial fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of aldosterone antagonists to inhibit myocardial fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aldosterone antagonists to inhibit myocardial fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-218328